FIXX Homology Medicines Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: FIXX

Price (delayed)

$0.55

Market cap

$31.86M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.28

Enterprise value

$31.09M

Homology Medicines, Inc. is a clinical-stage genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying ...

Highlights
FIXX's debt is down by 5% year-on-year
FIXX's equity has dropped by 58% year-on-year and by 26% since the previous quarter
FIXX's quick ratio is down by 49% year-on-year and by 26% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.homologymedicines.com

Key stats

What are the main financial stats of FIXX
Market
Shares outstanding
57.93M
Market cap
$31.86M
Enterprise value
$31.09M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.36
Price to sales (P/S)
16.25
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
15.88
Earnings
Revenue
$1.96M
EBIT
-$131.24M
EBITDA
-$128.94M
Free cash flow
-$101.75M
Per share
EPS
-$2.28
Free cash flow per share
-$1.76
Book value per share
$1.53
Revenue per share
$0.03
TBVPS
$2.42
Balance sheet
Total assets
$140.06M
Total liabilities
$51.85M
Debt
$28.34M
Equity
$88.21M
Working capital
$81.34M
Liquidity
Debt to equity
0.32
Current ratio
4.22
Quick ratio
4.08
Net debt/EBITDA
0.01
Margins
EBITDA margin
-6,585.1%
Gross margin
100%
Net margin
-6,697.5%
Operating margin
-6,323.9%
Efficiency
Return on assets
-71.3%
Return on equity
-97.6%
Return on invested capital
-90.1%
Return on capital employed
-114.3%
Return on sales
-6,702.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

FIXX stock price

How has the Homology Medicines stock price performed over time
Intraday
3.6%
1 week
-0.18%
1 month
-46.08%
1 year
-61.54%
YTD
-56.35%
QTD
-52.99%

Financial performance

How have Homology Medicines's revenue and profit performed over time
Revenue
$1.96M
Gross profit
$1.96M
Operating income
-$123.82M
Net income
-$131.14M
Gross margin
100%
Net margin
-6,697.5%
The operating margin has plunged by 53% YoY and by 39% from the previous quarter
FIXX's net margin is down by 40% since the previous quarter
Homology Medicines's revenue has decreased by 39% YoY and by 29% from the previous quarter
Homology Medicines's gross profit has decreased by 39% YoY and by 29% QoQ

Growth

What is Homology Medicines's growth rate over time

Valuation

What is Homology Medicines stock price valuation
P/E
N/A
P/B
0.36
P/S
16.25
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
15.88
The P/B is 84% below the 5-year quarterly average of 2.2 and 28% below the last 4 quarters average of 0.5
FIXX's equity has dropped by 58% year-on-year and by 26% since the previous quarter
The P/S is 88% less than the 5-year quarterly average of 138.5 and 31% less than the last 4 quarters average of 23.5
Homology Medicines's revenue has decreased by 39% YoY and by 29% from the previous quarter

Efficiency

How efficient is Homology Medicines business performance
FIXX's ROS is down by 40% from the previous quarter
The return on equity has declined by 22% since the previous quarter
Homology Medicines's return on invested capital has decreased by 18% QoQ
The ROA has contracted by 16% from the previous quarter

Dividends

What is FIXX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for FIXX.

Financial health

How did Homology Medicines financials performed over time
The total assets is 170% greater than the total liabilities
The current ratio has dropped by 50% year-on-year and by 26% since the previous quarter
FIXX's quick ratio is down by 49% year-on-year and by 26% since the previous quarter
FIXX's debt is 68% smaller than its equity
Homology Medicines's debt to equity has soared by 129% YoY and by 33% from the previous quarter
FIXX's equity has dropped by 58% year-on-year and by 26% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.